第一财经每日精选最热门大公司动态。 【今日推荐】 极端大风！美团、饿了么紧急提醒 据报道，受冷涡加强东移南下影响，11日下午至13日北京将出现一次极端大风、强降温天气过程。 美团方面11日午间表示，美团已向北京区域骑手发布了大风天气预警，提醒骑手防风慢行，谨防高 空坠物，如遇意外情况，可及时通过骑手App上报。在极端大风天气下，骑手可免费使用美团外卖 柜，美团将向骑手灵活提供恶劣天气补贴。饿了么方面表示，饿了么提前做好骑手配送安全和防风保 障，已成立"安全生产"专项小组，启动特殊天气下的应急机制，在确保人员安全情况下，保障城市、 社区民生需求，为大家提供更好的服务；同时也将根据属地要求和实际情况，对外卖服务持续进行调 整。（中新经纬） 盒马宣布面向中国外贸企业开放入驻 盒马发布公告，即日起面向外贸企业正式开放24小时绿色入驻通道，匹配高效的物流供应链支撑、 联合开发自有品牌创新商品，助力中国优质的外贸企业开拓国内市场。据悉，盒马欢迎百货品类（家 居用品、户外运动、宠物、美妆、母婴、康养等）外贸企业入驻，后续还将上线"外贸专区"。 字节跳动游戏业务将独立上市？回应：目前没有上市计划 4月11日，有消息称字节跳动 ...

医药板块观点更新&皓元医药深度汇报 20250410 2025-04-11 摘要 • 美国对等关税政策可能在未来 1-2 个季度影响医药行业，扰乱供应链，促 使医药贸易格局重塑，中国企业或加强与欧洲和美洲客户合作。若美国对 中国主导的血制品如白蛋白加征关税，可能导致国内供给紧张，推升价格， 利好国内生产企业。 • 皓元医药专注于分子砌块工具化合物、生化试剂及原料药中间体，预计 2025-2027 年收入和利润增速均超 15%-20%，受益于分子砌块市场国 产替代、海外收入提升及向创新药转型。 • 全球医药研发投入持续增加，预计到 2025 年市场规模将达到 3,000 多亿 美元，年均增长率约为 8%。中国医药研发投入增速更为显著，大约为 19%，高于全球平均水平，到 2025 年预计将达到 476 亿美元。 • 分子砌块全球市场规模预计 2024 年达 519 亿美元，2026 年增至 546 亿 美元，新药研发前端业务仍有较大发展空间。国产替代加速，本土品牌在 供货周期、价格和服务上具优势，逐步取代外资品牌。 • 皓元医药海外业务布局改善利润率，2021-2024 年海外毛利率稳定在 60%左右，国内毛利 ...

Core Viewpoint - WuXi AppTec's stock experienced a significant decline of 10.0% on April 7, indicating potential concerns among investors regarding the company's performance and market position [1]. Company Overview - WuXi AppTec, established in 2000, is located in Wuxi and primarily engages in research and development activities. The company has a registered capital of 29.53 billion RMB, with GE LI serving as the legal representative [1]. Shareholder Activity - Among WuXi AppTec's top shareholders is the China Europe Fund, which reduced its holdings in the company during the fourth quarter of the previous year. The fund has reported a year-to-date return of 4.45%, ranking 1657 out of 4592 in its category [1]. Fund Management - The fund manager of the China Europe Healthcare Mixed Fund is Ms. Ge Lan, who has a background in biomedical engineering from Northwestern University. She has held various research and fund management positions since joining China Europe Fund Management in October 2014 [4][5].

Group 1: Macroeconomic Insights - The recent reciprocal tariffs imposed by the US have significantly exceeded expectations, with the overall tariff rate on China reaching 65.7%, potentially reducing China's exports by 7-9 percentage points in 2025 and impacting GDP by over 1.0 percentage point [4] - The economic pressure from these tariffs is expected to accelerate the introduction of new policies, particularly those aimed at increasing leverage, including potential interest rate cuts and fiscal stimulus measures [4] - The report suggests that fiscal measures may include additional bond issuance, estimating that a 1 percentage point decline in exports would require a fiscal boost of approximately 1.3 trillion yuan [4] Group 2: Sector Performance - The report highlights that certain cyclical industries are entering a strong trend phase with low crowding, particularly in chemicals, non-ferrous metals, and steel, while the TMT sector shows high crowding and should be approached with caution [14] - The banking sector is expected to benefit from policy catalysts, with specific banks like Ningbo Bank and Postal Savings Bank recommended for their cyclical positioning [22] - The tungsten industry is noted for its strategic advantages, with companies that can ensure resource supply and high-end processing likely to benefit from the ongoing industry cycle [24] Group 3: Company-Specific Analysis - Xiaomi Group is projected to see revenue growth from 452.3 billion yuan in 2025 to 713.6 billion yuan by 2027, with a focus on improving gross margins and expanding its IoT business [38] - The report anticipates that Lekin Technology will achieve revenues of 26.4 billion yuan in 2025, driven by its AIoT platform and expanding product matrix, with a "buy" rating assigned [26] - The company Kai Lai Ying is expected to recover with a projected net profit of 10.9 billion yuan in 2025, supported by a favorable order environment and ongoing investment in R&D [35] Group 4: Retail Sector Developments - The company Kid King is focusing on a multi-channel strategy and aims to accelerate its AI incubation efforts, with projected revenues of 107 billion yuan by 2025 [33] - Aiying Room is optimizing its traditional store operations and expanding its new business formats, with expected revenues of 36.9 billion yuan in 2025 [34]

Core Viewpoint - WuXi AppTec's stock experienced a significant decline of 3.2% on April 2, 2023, indicating potential market concerns regarding the company's performance or external factors affecting investor sentiment [1]. Company Overview - WuXi AppTec was established in 2000 and is located in Wuxi, China, primarily engaged in research and experimental development [1]. - The company has a registered capital of 295,272.6521 million RMB, with GE LI (李革) serving as the legal representative [1]. Shareholder Information - E Fund's HuShen 300 Pharmaceutical ETF has entered WuXi AppTec's top ten shareholders, marking a new investment in the fourth quarter of the previous year [1]. - The ETF has recorded a year-to-date return of 3.75%, ranking 1143 out of 3442 in its category [1]. Fund Management - The fund manager for E Fund's HuShen 300 Pharmaceutical ETF is Yu Haiyan, who holds a master's degree in economics and has extensive experience in investment management [4][5].

Group 1 - Chengdu Xian Dao Pharmaceutical Development Co., Ltd. is planning a major asset restructuring to acquire approximately 65% of the shares of Nanjing Haina Pharmaceutical Technology Co., Ltd. in cash, which will make Chengdu Xian Dao the controlling shareholder of Haina Pharmaceutical [1] - Haina Pharmaceutical, established in 2001 with a registered capital of approximately 95.22 million, has developed into a comprehensive pharmaceutical R&D group covering new drug discovery, pharmaceutical research, process development, clinical research, and drug production [1] - Chengdu Xian Dao focuses on the discovery and optimization of small molecules and nucleic acid new drugs, leveraging four core technology platforms to create an internationally leading R&D system [2] Group 2 - The acquisition is viewed as a strategic move to extend Chengdu Xian Dao's operations downstream, enhancing its capabilities in the drug development process [2] - If the transaction is completed, it is expected to lead to effective resource integration and synergy, promoting rapid business development for Chengdu Xian Dao [2] - Chengdu Xian Dao reported a total revenue of approximately 427 million for 2024, a year-on-year increase of 14.99%, and a net profit of approximately 50.94 million, up 25.09% year-on-year [2]

与阿联酋签署合作协议 晶泰科技机器人自动化实验室出海 【深圳商报讯】（首席记者 彭琰）记者3月21日从晶泰科技了解到，晶泰科技日前与阿联酋王室谢 赫·哈马德办公室在阿布扎比正式签署商业合作协议，双方将在阿联酋共同建设中东地区首个自动传统 药物现代化研发实验室，首期投资3000万美元，开创中东地区传统医药研发新范式。此次合作也是晶泰 科技的自动化实验室首次规模化输出至阿拉伯世界。 该实验室项目计划于2025年4月正式启动首期建设，将服务于阿拉伯世界药物研发传承与创新，构 建全球领先的本土医药成分数据库与医药研发创新平台。同时，该项目还获得阿联酋国家战略新兴产业 转型机构的直接推动，未来晶泰科技将深化与阿联酋卫生部、药物监督管理局的多维度合作，为相关领 域研发创新的管理与审批奠定制度基础。 晶泰科技董事局主席温书豪表示，此次合作是中国自主研发的智能研发体系与质量标准的全球化验 证。晶泰科技正构建横跨欧亚的医药创新走廊，让自动化与数据驱动的研发范式成为传统医学升级的通 用语言。分析人士认为，此次合作是晶泰科技的高精度高柔性科学家机器人集群、高通量数据挖掘分析 平台等技术能力在药物发现领域的一次创新应用探索。晶泰科技 ...

李翀｜中信证券海外研究联席首席分析师 S1010522100001 海外研究｜美联储"Wait for greater clarity"：美联储2025年3月议息会议点评 美联储2025年3月议息会议维持政策利率不变，符合市场预期。本次点阵图显示今年目标利率中枢为3.9%，与2024年 12月会议点阵图持平，同时上调今年通胀预测和失业率预测、下调经济增速预测。"Wait for greater clarity"成为美 联储的新口号，"通胀暂时论"重出江湖，鲍威尔依旧认为长期通胀预期"well anchored"。当前"transitory inflation+ weaker growth+ high uncertainty"的组合对应点阵图显示的年内2次降息，我们认为三者中任何一者朝着美联储预期 的反向变化理论上都会导致降息次数削减。我们预计美联储年内降息次数小于或等于2次。市场方面，美联储此次议 息会议起到了"Fed Put"的作用，我们预计短期内市场情绪得到提振，美股市场有所反弹，但需警惕特朗普关税政策 再出变数。 风险因素：美国通胀超预期反弹；美国金融系统脆弱性超预期；美国劳动力市场超预期走弱；特朗普关 ...

证券代码：300404 证券简称：博济医药 公告编号：2025-005 博济医药科技股份有限公司 关于公司获得发明专利证书的公告 专利号：ZL 2022 1 0353061.0 专利申请日：2022 年 03 月 31 日 专 利权人 ：深圳博瑞医药科技有限公司；博济医药科技股份有限公司 授权公告日：2025 年 02 月 18 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，博济医药科技股份有限公司（以下简称"公司"）及全资子公司深圳 博瑞医药科技有限公司共同申请获得国家知识产权局颁发的一项发明专利证书， 具体情况如下： 发明名称：一种拟肽化合物及其制备 2019-nCoV 主蛋白酶抑制剂的用途 证书号：第 7743673 号 2025 年 2 月 21 日 1 本发明属于 1.1 类创新药研发技术领域，涉及一种新的拟肽化合物、其药学 上可接受的盐、其立体异构体或同位素标记物，并进一步公开其用于制备 2019-nCoV 主蛋白酶抑制剂的用途。本发明所述新分子实体，在已知药物结构基 础上进行创新、优化，使得其对 2019-nCoV 主蛋白酶的抑制活性 ...

一周IPO动态，覆盖港股、美股、A股。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 多点数智 港股｜挂牌上市 据IPO早知道消息，Dmall Inc.（多点数智有限公司，以下简称"多点"）于2024年12月6日正式 以"2586"为股票代码在港交所主板挂牌上市。 成立于2015年的多点主要为本地零售业的零售商提供零售数字化解决方案，业务覆盖中国大陆、香 港特别行政区、柬埔寨、新加坡、马来西亚、澳门特别行政 区、印尼、菲律宾及汶莱等国家或地 区。 2021年至2023年、以及今年上半年，多点已分别为236名、436名、533名以及444名客户提供服 务。 根据弗若斯特沙利文的资料，按2023年收入计算，多点是中国最大的零售数字化解决方案服务商， 市场份额为6.5%；同时也是亚洲第三大零售数字化解决方案服务商，市场份额为4.2%。 财务数据方面。2021年至2023年，多点的营收分别为8.48亿元、13.28亿元和15.85亿元；今年上 半年，多点的营收从2023年同期的7.64亿元增加22.9%至9.39亿元。 2021年至2023年、以及今年上半年，多点的毛利率分别为20.4%、 ...